



Maryland Prescription Drug Affordability Stakeholder Council
Meeting Agenda
Virtual
April 29, 2024 — 2:00pm

- I. Call Meeting to Order & Roll Call
- II. February 26, 2024 Meeting Minutes
- III. Opportunity for Public Comment¹
- IV. Cost Review Process Update- Discussion of Drugs Referred to the Stakeholder Council
Attachment A- incorporated herein, Drugs Referred to the Stakeholder Council
- V. Administrative Update
- VI. Co-Chair's Update
- VII. Adjournment

Please register for the Prescription Drug Affordability Stakeholder Council Meeting on April 29, 2024, at 2:00 PM [here](#). After registering, you will receive a confirmation email containing information about how to join the webinar.

Registration information for future meetings will be published on the PDAB website at pdab.maryland.gov, and shared with our [mailing list](#).²

¹ The public may submit written comments on the Board's pending decisions, or general comments regarding the Board's work, to comments.pdab@maryland.gov. For more information on presenting comments during the meeting, please visit the Board Meetings page at the PDAB's website.

² To subscribe to our mailing list, you must (1) enter your email address and submit your information and (2) select the PDAB's mailing list from the available options.



Appendix A- March 25, 2024 Drugs Referred to the Stakeholder Council

Drug	Drug Name	Dose Strength	Dose Strength Unit of Measure
BIKTARVY	Biktarvy	50-200-25	MG
DUPIXENT	Dupixent	300	MG/2ML
	Dupixent	300	MG/2ML
	Dupixent	200	MG/1.14ML
FARXIGA	Farxiga	10	MG
	Farxiga	5	MG
JARDIANCE	Jardiance	25	MG
	Jardiance	10	MG
	Jardiance	25	MG
	Jardiance	25	MG
OZEMPIC	Ozempic	2	MG/1.5ML
	Ozempic	2	MG/1.5ML
	Ozempic	4	MG/3ML
	Ozempic	8	MG/3ML
SKYRIZI	Skyrizi	150	MG/ML
	Skyrizi	75	MG/0.83ML
	Skyrizi Pen	150	MG/ML
TRULICITY	Trulicity	0.75	MG/0.5ML
	Trulicity	1.5	MG/0.5ML
	Trulicity	3	MG/0.5ML
	Trulicity	4.5	MG/0.5ML
VYVANSE	Vyvanse	40	MG
	Vyvanse	30	MG
	Vyvanse	70	MG
	Vyvanse	60	MG
	Vyvanse	50	MG
	Vyvanse	20	MG